کد مقاله | کد نشریه | سال انتشار | مقاله انگلیسی | نسخه تمام متن |
---|---|---|---|---|
2404160 | 1102956 | 2010 | 12 صفحه PDF | دانلود رایگان |
عنوان انگلیسی مقاله ISI
Is it cost-effective to introduce rotavirus vaccination in the Dutch national immunization program?
دانلود مقاله + سفارش ترجمه
دانلود مقاله ISI انگلیسی
رایگان برای ایرانیان
کلمات کلیدی
موضوعات مرتبط
علوم زیستی و بیوفناوری
ایمنی شناسی و میکروب شناسی
ایمونولوژی
پیش نمایش صفحه اول مقاله

چکیده انگلیسی
This study assessed whether the inclusion of two rotavirus (RV) vaccines in the Dutch national immunization programme is cost-effective. Costs and outcomes in unvaccinated and vaccinated populations are compared for a time period of 20 years. In the baseline, assuming competitive market forces in relation to vaccine costs, Rotarix® is more cost-effective than RotaTeq®, resulting in a cost-utility ratio (CUR) of € 53,000 per DALY (third payer perspective) and € 49,000 per DALY (societal perspective), but both considered as being not cost-effective. Vaccine-related costs, annual epidemic-size, and indirect protection are the major factors that determine cost-effectiveness of RV vaccination.
ناشر
Database: Elsevier - ScienceDirect (ساینس دایرکت)
Journal: Vaccine - Volume 28, Issue 14, 19 March 2010, Pages 2624–2635
Journal: Vaccine - Volume 28, Issue 14, 19 March 2010, Pages 2624–2635
نویسندگان
Marie-Josee J. Mangen, Yvonne T.H.P. van Duynhoven, Harry Vennema, Wilfrid van Pelt, Arie H. Havelaar, Hester E. de Melker,